RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. (RAPT): 2 pipeline candidates · ~37 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
36.7 months
D/E 0.09
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for RAPT Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7B
Cash
$37.9M
Quarterly Burn
$12.5M
Runway
36.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in RAPT Therapeutics, Inc.'s pipeline?
RAPT Therapeutics, Inc. (RAPT) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is RAPT Therapeutics, Inc.'s lead drug candidate?
RAPT Therapeutics, Inc.'s most advanced tracked candidate is rpt193 (Phase 2) for Atopic Dermatitis; Asthma.
What is RAPT Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, RAPT Therapeutics, Inc. has approximately 36.7 months of cash runway.
What is RAPT Therapeutics, Inc.'s market capitalization?
RAPT Therapeutics, Inc.'s market capitalization is approximately $1.7B.
Who is the CEO of RAPT Therapeutics, Inc.?
South San Francisco is the chief executive officer of RAPT Therapeutics, Inc. (RAPT).
Get the full picture on RAPT Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.